Trials / Active Not Recruiting
Active Not RecruitingNCT04599504
Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)
Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)
- Status
- Active Not Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the effectiveness of lisdexamfetamine medication as a treatment for loss-of-control eating and weight following bariatric surgery. This is a controlled test of whether, amongst non-responders to acute treatments, lisdexamfetamine medication results in superior outcomes compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lisdexamfetamine Dimesylate (Medication) | Medication will be taken daily in pill form. |
| OTHER | Placebo | Placebo will be inactive and taken daily in pill form. |
Timeline
- Start date
- 2022-01-02
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2020-10-22
- Last updated
- 2026-02-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04599504. Inclusion in this directory is not an endorsement.